Thomas N. Chase

Thomas N. Chase's AcademicInfluence.com Rankings

Thomas N. Chase

Biology

#10667

World Rank

#14016

Historical Rank

Neuroscience

#1668

World Rank

#1720

Historical Rank

biology Degrees

Download Badge

Biology

Thomas N. Chase's Degrees

Bachelors Biology Stanford University

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2026

Why Is Thomas N. Chase Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Thomas N. Chase's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. (1990) (2909)
Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. (1992) (542)
D1 dopamine receptor activation required for postsynaptic expression of D2 agonist effects. (1987) (466)
L-Dopa-Induced Release of Cerebral Monoamines (1970) (343)
Obligatory D-1/D-2 receptor interaction in the generation of dopamine agonist related behaviors. (1986) (328)
A comparison of the anatomical distribution of substance P and substance P receptors in the rat central nervous system (1984) (303)
Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism (2000) (263)
Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models (2001) (254)
Nuclear Factor κB Nuclear Translocation Upregulates c-Myc and p53 Expression during NMDA Receptor-Mediated Apoptosis in Rat Striatum (1999) (246)
Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration (1994) (236)
Autoradiographic distribution of substance P receptors in rat central nervous system (1983) (229)
Dopaminergic mechanisms and motor function: characterization of D-1 and D-2 dopamine receptor interactions. (1986) (205)
A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson’s disease (2003) (197)
Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats (1991) (196)
Continuous and intermittent levodopa differentially affect basal ganglia function (1989) (173)
Serotonin and central nervous system function. (1973) (161)
Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys. (1999) (160)
Nuclear Factor-κB Contributes to Excitotoxin-Induced Apoptosis in Rat Striatum (1998) (160)
Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and l-DOPA administration (1998) (155)
Evoked Release of Norepinephrine and Serotonin from Brain Slices: Inhibition by Lithium (1968) (148)
The D1 dopamine receptor in the rat brain: Quantitative autoradiographic localization using an iodinated ligand (1988) (147)
EFFECT OF IONS ON STIMULUS‐INDUCED RELEASE OF AMINO ACIDS FROM MAMMALIAN BRAIN SLICES (1969) (138)
Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists. (1989) (137)
Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD (2005) (129)
Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal nmda receptor subunits (1999) (126)
Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms (2000) (125)
NMDA receptor blockade reverses motor response alterations induced by levodopa. (1994) (124)
Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade (1995) (121)
Improvement in tardive dyskinesia after muscimol therapy. (1979) (120)
Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. (2000) (118)
Dopaminergic modulation of striatal neuropeptides: differential effects of D1 and D2 receptor stimulation on somatostatin, neuropeptide Y, neurotensin, dynorphin and enkephalin (1992) (118)
NOREPINEPHRINE METABOLISM IN THE CENTRAL NERVOUS SYSTEM OF MAN: STUDIES USING 3‐METHOXY‐4‐HYDROXYPHENYLETHYLENE GLYCOL LEVELS IN CEREBROSPINAL FLUID (1973) (116)
Dietary regulation of brain tryptophan metabolism by plasma ratio of free tryptophan and neutral amino acids in humans (1974) (114)
Muscimol: GABA agonist therapy in schizophrenia. (1978) (113)
RELEASE OF [3H]SEROTONIN FROM BRAIN SLICES 1 (1969) (102)
Release of [3H]dopamine byl-5-hydroxytryptophan (1972) (102)
Autoradiographic localization of substance P receptors in rat medulla: Effect of vagotomy and nodose ganglionectomy (1984) (93)
Stimulation of N-methyl-d-aspartate receptors induces apoptosis in rat brain (1996) (92)
MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats (1996) (91)
Cholecystokinin-octapeptide effects on conditioned-avoidance behavior, stereotypy and catalepsy. (1982) (89)
Effect of diazepam on fate of intracisternally injected serotonin-C14. (1970) (89)
D-1 dopamine receptor changes after striatal quinolinic acid lesion. (1987) (88)
Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease (1997) (86)
NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats (2004) (81)
Dopamine: Stimulation-Induced Release from Central Neurons (1971) (79)
A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model (2008) (73)
NF-κB contributes to 6-hydroxydopamine-induced apoptosis of nigral dopaminergic neurons through p53 (2007) (70)
Serotonin Release from Brain Slices by Electrical Stimulation: Regional Differences and Effect of LSD (1967) (70)
Stimulus-induced Release of Substances from Olfactory Bulb using the Push–Pull Cannula (1968) (68)
Muscarinic Receptor Stimulation Induces Translocation of an α-Synuclein Oligomer from Plasma Membrane to a Light Vesicle Fraction in Cytoplasm* (2001) (65)
Nuclear factor-kappa B contributes to excitotoxin-induced apoptosis in rat striatum. (1998) (65)
Striatal glutamatergic mechanisms and extrapyramidal movement disorders (2009) (65)
Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson's disease (2002) (62)
5-Hydroxyindoleacetic acid in spinal fluid: relative contribution from brain and spinal cord (1973) (62)
Metabolism of some phenylethylamines and their beta-hydroxylated analogs in brain. (1969) (61)
A role for bombesin in sensory processing in the spinal cord (1984) (59)
L‐dopa in parkinsonism (1972) (58)
Effects of cannabinoid receptor stimulation and blockade on catalepsy produced by dopamine receptor antagonists. (1996) (58)
Responses of substantia nigra pars reticulata neurons to GABA and SKF 38393 in 6-hydroxydopamine-lesioned rats are differentially affected by continuous and intermittent levodopa administration (1990) (57)
Quantitative autoradiographic localization of D-1 dopamine receptors in the rat brain: Use of the iodinated ligand [125I]SCH 23982 (1986) (56)
The cannabinoid agonists WIN 55,212-2 and CP 55,940 attenuate rotational behavior induced by a dopamine D1 but not a D2 agonist in rats with unilateral lesions of the nigrostriatal pathway (1995) (56)
The circadian variation of catecholamine metabolism in the subhuman primate (1978) (55)
Dopaminergic mechanisms in hemiparkinsonian monkeys (1987) (54)
The ventral surface of the medulla in the rat: Pharmacologic and autoradiographic localization of GABA-induced cardiovascular effects (1984) (54)
Interaction of D1 and D2 dopamine receptors in the expression of dopamine agonist induced behaviors. (1986) (53)
Stimulation of Prolactin and Growth Hormone Secretion by Muscimol, a γ-Aminobutyric Acid Agonist (1978) (53)
Opposite effects of NMDA and AMPA receptor blockade on catalepsy induced by dopamine receptor antagonists. (1993) (52)
Substance P enhancement of passive and active avoidance conditioning in mice (1983) (51)
Des-tyrosine-γ-endorphin administration in chronic schizophrenics. A preliminary report (1981) (50)
PCP‐induced alterations in cerebral glucose utilization in rat brain: Blockade by metaphit, a PCP‐receptor‐acylating agent (1987) (50)
Dopamine D1 receptor-stimulated release of acetylcholine in rat striatum is mediated indirectly by activation of striatal neurokinin1 receptors. (1994) (49)
Brain Catecholamines and Human Sleep (1971) (49)
Down's Syndrome: Transport, Storage, and Metabolism of Serotonin in Blood Platelets (1972) (49)
The circadian variation in dopamine metabolism in the subhuman primate (1977) (49)
Overexpression of neurotrophin receptor p75 contributes to the excitotoxin-induced cholinergic neuronal death in rat basal forebrain (2000) (48)
Dopamine D1 receptor modulation of pilocarpine-induced convulsions (1990) (48)
Positron emission tomographic studies of regional cerebral glucose metabolism in idiopathic dystonia. (1988) (48)
Biological Sciences: Reduction of Catechol-O-methyl-transferase Activity by Chronic L-Dopa Therapy (1971) (47)
Demonstration and Distribution of Kassinin‐Like Material (Substance K) in the Rat Central Nervous System (1985) (45)
Brain choline acetyltransferase activity and neuropeptide Y concentrations in Alzheimer's disease (1986) (45)
Effect of probenecid on levels of cyclic AMP in human cerebrospinal fluid (1972) (45)
Autoradiographic localization of substance P receptors using 125I substance P (1982) (44)
Free radical scavenger OPC-14117 attenuates quinolinic acid-induced NF-kappaB activation and apoptosis in rat striatum. (1999) (44)
Behavioral effects of chronic exposure to selective D-1 and D-2 dopamine receptor agonists. (1988) (42)
EFFECT OF DIAZEPAM AND PENTOBARBITAL ON AMINOOXYACETIC ACID‐INDUCED ACCUMULATION OF GABA (1977) (42)
Differential effect of subthalamic nucleus ablation on dopamine D1 and D2 agonist-induced rotation in 6-hydroxydopamine-lesioned rats (1992) (42)
Prostaglandin A(1) protects striatal neurons against excitotoxic injury in rat striatum. (2001) (41)
Methyldopahydrazine as an adjunct to L‐dopa therapy in parkinsonism (1972) (41)
Substance P increases release of acetylcholine in the dorsal striatum of freely moving rats (1993) (40)
GABAA and GABAB receptors differentially regulate striatal acetylcholine release in vivo (1993) (40)
Autoradiographic distribution of substance K binding sites in rat gastrointestinal tract: a comparison with substance P. (1984) (38)
Substance P facilitation of memory: effects in an appetitively motivated learning task. (1986) (37)
Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. (1997) (36)
Cholecystokinin-octapeptide fragments: binding to brain cholecystokinin receptors. (1984) (35)
Differential effects of chronic dopamine D1 and D2 receptor agonists on rotational behavior and dopamine receptor binding. (1993) (34)
Co-stimulation of cyclic-AMP-linked metabotropic glutamate receptors in rat striatum attenuates excitotoxin-induced nuclear factor-κB activation and apoptosis (1999) (34)
Metabolism of tyramine-3H and octopamine-3H by rat brain. (1969) (33)
Prolonged infusion of quinolinic acid into rat striatum as an excitotoxic model of neurodegenerative disease (1991) (33)
Dopamine D1 receptor stimulation but not dopamine D2 receptor stimulation attenuates haloperidol-induced behavioral supersensitivity and receptor up-regulation. (1993) (32)
Susceptibility of striatal neurons to excitotoxic injury correlates with basal levels of Bcl-2 and the induction of P53 and c-Myc immunoreactivity (2005) (32)
N-methyl-d-aspartate receptor blockade differentially modifies regional cerebral metabolic responses to D1 and D2 dopamine agonists in rats with a unilateral 6-hydroxydopamine lesion (1993) (32)
NMDA and non-NMDA receptor-stimulated IκB-α degradation: differential effects of the caspase-3 inhibitor DEVD·CHO, ethanol and free radical scavenger OPC-14117 (2000) (31)
The effects of striatal lesion on turning behavior and globus pallidus single unit response to dopamine agonist administration. (1990) (31)
Endogenous excitatory amino acids tonically stimulate striatal acetylcholine release through NMDA but not AMPA receptors (1994) (31)
Drug-induced Release of 3H-Norepinephrine and 3H-Serotonin from Brain Slices (1970) (30)
Deafferentation causes a loss of presynaptic bombesin receptors and supersensitivity of substance P receptors in the dorsal horn of the cat spinal cord (1985) (30)
Synergy between a selective D1 antagonist and a selective D2 antagonist in the induction of catalepsy (1989) (30)
Tolerance to a suprathreshold dose of L-Dopa in MPTP mice: effects of glutamate antagonists (1999) (29)
Comparison of cholinergic drug effects on regional brain glucose consumption in rats and humans by means of autoradiography and positron emission tomography (1994) (29)
Nootropic drugs in Alzheimer's disease (1991) (29)
CATECHOLAMINE METABOLISM IN THE DOG: COMPARISON OF INTRAVENOUSLY AND INTRAVENTRICULARLY ADMINISTERED [14C]DOPAMINE AND [3H]NOREPINEPHRINE (1971) (29)
Striatal molecular mechanisms and motor dysfunction in Parkinson's disease. (2001) (27)
Excitatory amino acid receptor antagonists modify regional cerebral metabolic responses to levodopa in 6-hydroxydopamine-lesioned rats (1994) (26)
Modification of cerebral ischemic damage by anesthetics (1977) (26)
Supersensitivity to a D-1 dopamine receptor agonist and subsensitivity to a D-2 receptor agonist following chronic D-1 receptor blockade. (1988) (25)
Influence of previous exposure to levodopa on the interaction between dizocilpine and dopamine D1 and D2 agonists in rats with 6-hydroxydopamine-induced lesions. (1993) (25)
Chronic Exposure to MPTP as a Primate Model of Progressive Parkinsonism: A Pilot Study with a Free Radical Scavenger (1998) (25)
Effect of anticonvulsants on brain serotonin. (1969) (25)
Substance p reversal of electroconvulsive shock and cycloheximide-induced retrograde amnesia. (1983) (25)
D1 and D2 dopamine receptor-mediated mechanisms and behavioral supersensitivity (1993) (25)
CCK26–33 Degrading Activity in Brain and Nonneural Tissue: A Metalloendopeptidase (1985) (25)
Vasopressin studies in Alzheimer's disease (1982) (25)
Bromocriptine and CF 25-397 in the treatment of tardive dyskinesia. (1980) (24)
Stimulation-induced release of serotonin. (1968) (24)
Effects of cholinergic agonists on regional brain energy metabolism in the scopolamine-treated rat (1992) (23)
Dopamine Neuronal Tracts in Schizophrenia: Their Pharmacology and in Vivo Glucose Metabolism (1988) (23)
Release of ( 3 H)dopamine by L-5-hydroxytryptophan. (1972) (22)
Distinct binding sites for substance P and neurokinin A (substance K): Co-transmitters in rat brain (1985) (22)
Neurohumoral mechanisms in the brain slice. (1970) (21)
New evidence for taurine biosynthesis in man obtained from 18O2 inhalation studies. (1986) (21)
Regional cerebral glucose metabolism compared in rodents and humans (1991) (21)
L‐dopa does not affect electron transfer chain enzymes and respiration of rat muscle mitochondria (1991) (21)
The kappa-opioid receptor agonist spiradoline differentially alters the rotational response to dopamine D1 and D2 agonists. (1991) (21)
Gene transfer of constitutively active protein kinase C into striatal neurons accelerates onset of levodopa-induced motor response alterations in parkinsonian rats (2003) (21)
Down's syndrome (1972) (20)
Attenuation of D-1 antagonist-induced D-1 receptor upregulation by concomitant D-2 receptor blockade. (1987) (20)
Tolerance to the anti-avoidance properties of cholecystokinin-octapeptide (1983) (20)
Products of cholecystokinin (CCK)-octapeptide proteolysis interact with central CCK receptors (1985) (18)
NBQX inhibits AMPA-induced locomotion after injection into the nucleus accumbens (1993) (18)
MK-801 reverses effects of chronic levodopa on D1 and D2 dopamine agonist-induced rotational behavior (1995) (18)
Glutamate metabotropic receptor agonist 1S,3R-ACPD induces internucleosomal DNA fragmentation and cell death in rat striatum (1997) (18)
Behavioral evaluation of the anti-excitotoxic properties of MK-801: Comparison with neurochemical measurements (1989) (18)
Intravenous probenecid loading (1976) (18)
Identification of D1-dopamine receptor in chicken embryo retina with [125I]SCH 23982 (1988) (17)
Neuroprotective effects of prostaglandin A1 in animal models of focal ischemia (2005) (17)
ANALYSIS OF [3H]NEUROTENSIN RECEPTORS BY COMPUTERIZED DENSITOMETRY: VISUALIZATION OF CENTRAL AND PERIPHERAL NEUROTENSIN RECEPTORS (1982) (17)
The neurokinin1 receptor antagonist CP-99,994 reduces catalepsy produced by the dopamine D2 receptor antagonist raclopride: correlation with extracellular acetylcholine levels in striatum. (1995) (17)
Tamoxifen effect on L-DOPA induced response complications in parkinsonian rats and primates (2007) (16)
Daily fluctuation in the concentration on cAMP in the conscious primate brain (1977) (16)
D-1/D-2 dopamine receptor interactions in the regulation of extrapyramidal motor function: studies in animal models and parkinsonian patients. (1986) (15)
Pharmacologic studies of tardive dyskinesia. (1980) (15)
Effect of long-term haloperidol treatment on striatal neuropeptides: Relation to stereotyped behavior (1996) (14)
Intracerebroventricular injection of cholecystokinin octapeptide elevates plasma prolactin levels through stimulation of vasoactive intestinal polypeptide. (1987) (13)
Striatal D1 dopamine receptor morphochemistry following continuous or intermittent l-DOPA replacement therapy (1991) (12)
GABA dysfunction in the pathophysiology of tardive dyskinesia. (1985) (12)
Preparative purification of the peptide des-enkephalin γ-endorphin (1981) (11)
Autoradiographic visualization of substance P receptors in rat brain. (1983) (11)
Cholecystokinin octapeptide analogues stable to brain proteolysis (1985) (11)
Dextromethorphan does not protect against quinolinic acid neurotoxicity in rat striatum (1988) (10)
Differential responses in prolactin levels induced by naloxone in humans (1985) (10)
A comparison of peripheral and central effects of CCK8 on water-reinforced operant responding. (1985) (9)
NMDA and non-NMDA receptor-stimulated IkappaB-alpha degradation: differential effects of the caspase-3 inhibitor DEVD.CHO, ethanol and free radical scavenger OPC-14117. (2000) (9)
Cholecystokinin‐mediated Synaptic Function and the Treatment of Neuropsychiatric Disease (1985) (9)
Effects of kappa receptor agonists on D1 and D2 dopamine agonist and antagonist-induced behaviors (2005) (9)
Dopamine histofluorescence: restoration in mammalian brain tissues prepared several hours post mortem. (1973) (9)
Elevation of plasma prolactin concentrations by intravenous SCH 23390 and SKF 38393 in conscious rats. (1987) (9)
Chromatography of AC-ASP-TYR-MET-GLY-TRP-MET-ASP-NH2 on the Horizontal flow-Through Coil Planet Centrifuge and the High-Speed Multi-Layer Coil Planet Centrifuge (1984) (8)
Minimized tolerance to the suppressive effects of CCK8 on operant responding. (1983) (8)
Stimulation of prolactin and growth hormone secretion by muscimol, a gamma-aminobutyric acid agonist. (1978) (7)
Effect of chronic D-1 and/or D-2 dopamine antagonist treatment on SKF 38393-induced non-stereotyped grooming (2005) (7)
Des-tyrosine-gamma-endorphin administration in chronic schizophrenics. A preliminary report. (1981) (6)
Effects of SCH 32615, an enkephalinase inhibitor, on D-1 and D-2 dopamine receptor-mediated behaviors (1995) (6)
ERGOT DERIVATIVES IN THE TREATMENT OF PSYCHOTIC AND HYPERKINETIC DISORDERS (1979) (6)
Caerulein treatment of Parkinson's disease. (1985) (6)
Reduction of catechol-O-methyl-transferases activity by chronic L-dopa therapy. (1971) (6)
Role of D1 and D2 Dopamine Receptors in Pilocarpine-Induced Seizures (1991) (6)
Neuronal cholecystokinin and schizophrenia: pathogenic and therapeutic studies (1986) (6)
Purification of a cholecystokinin fragment peptide in the horizontal flow-through coil planet centrifuge. (1984) (6)
Effect of monoamine oxidase inhibitors on the disposition of intracisternally administered metaraminol-3H. (1970) (5)
Effects of chronic Levodopa on D1 and D2 receptor-mediated striatal output (1992) (5)
INFLUENCE OF GONADAL STEROIDS ON PROLACTIN RESPONSE TO NALOXONE IN HUMANS (1983) (4)
Central cholecystokinin octapeptide reduces glucose utilization in subcortical but not cortical rat brain. (1987) (3)
Effect of Gi protein ADP-ribosylation induced by pertussis toxin on dopamine-mediated behaviors. (1991) (3)
5-hydroxyindoleacetic cid in spinal fluid: relative contribution from brain and spinal cord. (1973) (2)
Effects of Scopolamine on Human Brain Glucose Consumption (1995) (2)
Haloperidol- and SCH23390-induced dopaminergic supersensitivities are not additive in the rat (2004) (2)
Suppression of Levodopa‐Induced Dyskinesias by an NMDA Receptor Antagonist in MPTP‐Treated Monkeys (1995) (1)
Dopamine histofluorescence in post-mortem specimens of human and rat striatum. (1974) (1)
GABA agonist effect on cognitive dysfunction in schizophrenic subjects (1979) (1)
Do the Effects of Muscarinic Receptor Blockade on Brain Glucose Consumption Mimic the Cortical and Subcortical Metabolic Pattern of Alzheimer’s Disease in Normal Volunteers ? (1995) (1)
D-1 dopamine agonist administration reduces the threshold for convulsions produced by pilocarpine. (1989) (1)
The circadian pattern of catcholamine metabolites and cAMP in the cerebrospinal fluid of subhuman primates. (1976) (1)
DOPAMINE HISTOFLUORESCENCE IN POST-MORTEM SPECIMENS OF HUMAN AND RAT STRIATUM (1975) (1)
State of DA/ACh balance after chronic treatment with haloperidol and with THIP in rats. (1984) (1)
Cholecystokinin Octapeptide's Effect on Local Cerebral Glucose Utilization in the Laboratory Rat (1985) (1)
FUNCTIONAL STUDIES OF CHOLECYSTOKININ OCTAPEPTIDE IN MAMMALIAN CNS (1984) (0)
D 1 but not d 2 dopamine receptor stimulation reduces the threshold for pilocarpine induced epileptic activity in rats (1988) (0)
D 1 and d 2 dopamine system interactions in the 1 methyl 4 phenyl 1 2 3 6 tetrahydropyridine lesioned monkey (1986) (0)
Electrically stimulated release of norepinephrine-H3 and serotonin-H3 from mammalian brain slices: a model for studying the effects of drugs on putative central neurotransmitters. (1969) (0)
Down's Syndrome: Transport, Storage, and Metabolism of Serotonin in Blood Platelets (1972) (0)
Alzheimer's dementia. (1995) (0)
Protein kinase A inhibitor reverses levodopa-induced motor response alterations in the semi-Parkinsonian rat (1997) (0)
Novel strategies for the palliative treatment of Parkinson's disease (1998) (0)
Drs. Tamminga and Chase Reply (1979) (0)
Effects of vasopressin on multiple fixed-ratio fixed-interval schedules of reinforcement (1985) (0)